# S1613 (NCT03365882)

> S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

No report yet. It can be ordered.

- Drugs tested: trastuzumab plus pertuzumab
- Indication: RAS/BRAF wild-type, HER2-positive metastatic colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03365882
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Colon Adenocarcinoma; ERBB2 Gene Amplification; Rectal Adenocarcinoma; Recurrent Colon Carcinoma; Recurrent Rectal Carcinoma; Stage III Colon Cancer AJCC v7; Stage III Rectal Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Colon Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7
- Interventions: Cetuximab; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Pertuzumab; Trastuzumab; HER-2 testing
- Enrollment: 240
- Primary outcome: Progression-free Survival(PFS)

## Indexed commentary on S1613 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=s1613-nct03365882